<DOC>
	<DOCNO>NCT00587275</DOCNO>
	<brief_summary>The purpose project test safe well AST-120 , investigational product , work treat much acid stomach . Patients randomly assign one two group , AST-120 placebo first four week study . The patient switch group ( AST-120 placebo ) follow four week .</brief_summary>
	<brief_title>Safety Efficacy AST-120 Patients With GERD Who Continue Symptomatic Standard Dose PPI</brief_title>
	<detailed_description>This double-blind , randomize , placebo-controlled , crossover trial 20 patient confirm persistent GERD symptom ( least twice weekly ) standard course PPI , abnormal bile reflux level normal esophageal acid exposure randomize initially receive either AST-120 placebo period 4 week two week screen period . After washout period one week , patient cross opposite blind treatment . The experimental drug AST-120 compose black , odorless spherical carbon particles 2g sachet ( aluminum foil pouch ) . The placebo consist microcrystalline cellulose sphere , Celphere CP-305 , stain match appearance AST-120 , 2g sachet ( aluminum foil pouch ) . Both AST-120 placebo oral ( take mouth ) preparation . Both tasteless . Take product , patient tear open sachet , drop content directly tongue wash 8 ounce water . Patients continue receive previously prescribe PPI throughout duration trial . In addition , patient allow 6 Gelusil tablet daily `` rescue medication '' . Patients expect participate approximately 5 in-clinic visit . During visit , patient undergo number test include : comprehensive physical , hematology panel , urine pregnancy test pre-menopausal female , completion Gastroesophageal Reflux Disease Symptom Assessment Scale ( GSAS ) Short-Form-36 ( SF-36 ) Quality Life Form upper endoscopy perform determine extent esophageal inflammation . Patients allow continue previously prescribe PPI change may take 6 Gelusil tablet per day . The following therapy must discontinue take trial : H2receptor antagonist , NSAIDs , Baclofen Antacids ( OTC prescription ) .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<criteria>Body weight 40 136 kg ( 88 300 lb ) Recent history GERD relate symptom ( least twice weekly ) confirm screening . Recent history 8 week PPI treatment without significant improvement Abnormal bilirubin level assess Bilitec Normal esophageal pH value ( pH &lt; 4.0 &lt; 4.2 % time calculate 24 hour period ) Platelet count ( thrombocyte ) &gt; 100,000/ÂµL Normal Hgb Hct level Able willing comply protocol procedure plan duration study Able willing understand , sign date inform consent document , authorize access protect health information . Females must postmenopausal , surgically incapable bearing child , practice reliable method birth control ( hormonal contraceptive , intrauterine device , spermicide barrier ) . Partner/spouse sterility may also qualify Investigator 's discretion . Females childbearing potential must negative urine pregnancy test baseline . Concurrent GI pathology could interfere course study ( e.g. , erosive esophagitis , malabsorption , cirrhosis , ascites , bleed ulcer , diabetes , scleroderma , nonGI myopathy neuropathy etc . ) Note : patient Barrett 's esophagus ( short segment define &lt; 3 cm ) include . Patients cancer undergo chemotherapy treatment cancer Patients history upper GI surgery Patients GERD complication stricture esophagus Contraindication continue PPI treatment Patients require concomitant use NSAIDs duration study Uncontrolled systemic disease Diagnosis psychiatric disorder within past 2 year stable dose medication least 6 month Other major physical psychiatric illness previous 6 month determine treat physician Known hypersensitivity contraindication component test product ( study drug ) diagnostics use Participation another study within eight ( 8 ) week prior randomization Unable attend visit require protocol Pregnant , breast feeding , plan become pregnant study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Gastroesophageal Reflux Disease</keyword>
	<keyword>GERD</keyword>
</DOC>